The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities
The tumor microenvironment (TME) regulates essential tumor survival and promotion functions. Interactions between the cellular and structural components of the TME allow cancer cells to become invasive and disseminate from the primary site to distant locations, through a complex and multistep metastatic cascade. Tumor-associated M2-type macrophages have growth-promoting and immunosuppressive functions; mesenchymal cells mass produce exosomes that increase the migratory ability of cancer cells; cancer associated fibroblasts (CAFs) reorganize the surrounding matrix creating migration-guiding tracks for cancer cells. In addition, the tumor extracellular matrix (ECM) exerts determinant roles in disease progression and cancer cell migration and regulates therapeutic responses. The hypoxic conditions generated at the primary tumor force cancer cells to genetically and/or epigenetically adapt in order to survive and metastasize. In the circulation, cancer cells encounter platelets, immune cells, and cytokines in the blood microenvironment that facilitate their survival and transit. This review discusses the roles of different cellular and structural tumor components in regulating the metastatic process, targeting approaches using small molecule inhibitors, nanoparticles, manipulated exosomes, and miRNAs to inhibit tumor invasion as well as current and future strategies to remodel the TME and enhance treatment efficacy to block the detrimental process of metastasis.
Top-30
Journals
|
5
10
15
20
25
|
|
|
Cancers
22 publications, 6.36%
|
|
|
International Journal of Molecular Sciences
12 publications, 3.47%
|
|
|
Frontiers in Immunology
10 publications, 2.89%
|
|
|
Frontiers in Oncology
8 publications, 2.31%
|
|
|
Pathology Research and Practice
7 publications, 2.02%
|
|
|
Medical Oncology
6 publications, 1.73%
|
|
|
Frontiers in Cell and Developmental Biology
5 publications, 1.45%
|
|
|
Biomedicines
5 publications, 1.45%
|
|
|
Oncology Letters
4 publications, 1.16%
|
|
|
Pharmaceuticals
4 publications, 1.16%
|
|
|
Frontiers in Pharmacology
4 publications, 1.16%
|
|
|
Scientific Reports
4 publications, 1.16%
|
|
|
Discover Oncology
4 publications, 1.16%
|
|
|
Journal of Translational Medicine
3 publications, 0.87%
|
|
|
Cells
3 publications, 0.87%
|
|
|
Molecular Cancer
3 publications, 0.87%
|
|
|
Critical Reviews in Oncology/Hematology
3 publications, 0.87%
|
|
|
Phytomedicine
3 publications, 0.87%
|
|
|
Oral Oncology Reports
3 publications, 0.87%
|
|
|
International Journal of Oncology
3 publications, 0.87%
|
|
|
Molecular Biology Reports
3 publications, 0.87%
|
|
|
ACS Applied Bio Materials
3 publications, 0.87%
|
|
|
International Journal of Biological Macromolecules
3 publications, 0.87%
|
|
|
Apoptosis : an international journal on programmed cell death
2 publications, 0.58%
|
|
|
Journal of Controlled Release
2 publications, 0.58%
|
|
|
Advances in Cancer Biology - Metastasis
2 publications, 0.58%
|
|
|
Communications Biology
2 publications, 0.58%
|
|
|
Biology
2 publications, 0.58%
|
|
|
Oral Oncology
2 publications, 0.58%
|
|
|
5
10
15
20
25
|
Publishers
|
10
20
30
40
50
60
70
|
|
|
Springer Nature
69 publications, 19.94%
|
|
|
Elsevier
69 publications, 19.94%
|
|
|
MDPI
66 publications, 19.08%
|
|
|
Frontiers Media S.A.
34 publications, 9.83%
|
|
|
Wiley
22 publications, 6.36%
|
|
|
Spandidos Publications
8 publications, 2.31%
|
|
|
Cold Spring Harbor Laboratory
8 publications, 2.31%
|
|
|
Taylor & Francis
6 publications, 1.73%
|
|
|
American Chemical Society (ACS)
6 publications, 1.73%
|
|
|
Hindawi Limited
4 publications, 1.16%
|
|
|
Bentham Science Publishers Ltd.
4 publications, 1.16%
|
|
|
Royal Society of Chemistry (RSC)
4 publications, 1.16%
|
|
|
Oxford University Press
3 publications, 0.87%
|
|
|
IntechOpen
3 publications, 0.87%
|
|
|
AME Publishing Company
3 publications, 0.87%
|
|
|
Research Square Platform LLC
3 publications, 0.87%
|
|
|
IOP Publishing
2 publications, 0.58%
|
|
|
American Association for Cancer Research (AACR)
2 publications, 0.58%
|
|
|
Morion LLC
2 publications, 0.58%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.58%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 0.58%
|
|
|
Baishideng Publishing Group
2 publications, 0.58%
|
|
|
Brieflands
2 publications, 0.58%
|
|
|
Begell House
1 publication, 0.29%
|
|
|
Walter de Gruyter
1 publication, 0.29%
|
|
|
Life Science Alliance, LLC
1 publication, 0.29%
|
|
|
Allerton Press
1 publication, 0.29%
|
|
|
American Society for Clinical Investigation
1 publication, 0.29%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.29%
|
|
|
10
20
30
40
50
60
70
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.